The global drug discovery informatics market size is expected to reach USD 6.86 billion by 2030, registering a CAGR of 11.2% from 2023 to 2030, according to a new report by Grand View Research, Inc. Use of drug discovery software for gaining market intelligence owing to several advantages, such as rapid drug design & synthesis, efficient tracking of disease evolution, and data integrity management, has increased significantly among the researchers in the recent years, driving the industry growth.
The growing demand for novel molecules is driving the adoption of informatics solutions targeted towards speeding up the entire drug discovery process by identifying rational drug molecules via the target macromolecule interaction. Companies operating in the market are receiving funding for expanding their drug discovery platforms, further supplementing the market growth. For instance, in September 2020, Ardigen signed an agreement with the National Centre for Research and Development to access its funding for developing novel technology.
This technology was aimed at revolutionizing the development of T-cell receptors-based therapies for immuno-oncology. Ardigen has previously developed a neoantigen prediction platform namely, ArdImmune Vax, which deploys ready-to-use Artificial Intelligence (AI) and bioinformatics solutions for the identification of optimal sets of neoantigens as targets for adoptive cell therapies and cancer vaccines. In addition, chemical informatics solutions have gained considerable traction in the past year, particularly in addressing the needs associated with the recent Covid-19 pandemic.
For instance, a research study performed in January 2021 showcased the application of chemical digital solutions in accelerating the search of SARS-CoV-2 Mpro inhibitors by data analysis of previous activity data of SARS-CoV main protease (Mpro) inhibitors. In addition, the QSAR models helped in the data mining of molecules for rapid Covid-19 drug discovery. Hence, the need to facilitate drug development for Covid-19 is expected to propel the industry expansion over the coming years.
Request a free sample copy or view report summary: Drug Discovery Informatics Market Report
The drug development workflow segment is projected to exhibit the highest compound annual growth rate (CAGR) of 10.9% from 2022 to 2030 owing to a rise in the number of drug candidates in the clinical development phase
The discovery informatics segment accounted for the largest revenue share of around 60% in 2022, with a major focus on developing precision medicines. Precision medicine revolves around providing personalized medical care tailored to an individual's genetic and molecular profile.
Led by the U.S., North America led the global market in 2022 due to the presence of key market players and established R&D infrastructure in the country
Key industry participants focus on strategic acquisitions to sustain the market competition
Grand View Research has segmented the global drug discovery informatics market based on workflow, services, and region:
Drug Discovery Informatics Workflow Outlook (Revenue, USD Billion, 2018 - 2030)
Discovery Informatics
Biocontent Management
Drug Discovery Informatics Services Outlook (Revenue, USD Billion, 2018 - 2030)
Sequence Analysis Platforms
Molecular Modelling
Docking
Clinical Trial Data Management
Others
Drug Discovery Informatics Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Sweden
Norway
Denmark
Asia Pacific
China
Japan
India
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
Saudi Arabia
South Africa
UAE
Kuwait
List Of Key Players Drug Discovery Informatics Market
Certara
Boehringer Ingelheim International GmbH
Infosys Ltd.
Charles River Laboratories
Collaborative Drug Discovery, Inc.
Eurofins DiscoverX Products
Jubliant Biosys
Selvita
Novo Informatics Pvt. Ltd.
ChemAxon Ltd.
Albany Molecular Research Inc.
Oracle
Accenture
Agilent Technologies, Inc.
Illumina, Inc.
"The quality of research they have done for us has been excellent..."